IA
ORIC icon

IFP Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

IFP Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.76K Hold
297
– – ﹤0.01% 3691
2025
Q4 		$2.43K Hold
297
– – ﹤0.01% 3767
2025
Q3 		$3.56K Hold
297
– – ﹤0.01% 3439
2025
Q2 		$3.02K Buy
297
+285
+2,375% +$1.91K ﹤0.01% 3698
2025
Q1 		$67 Hold
12
– – ﹤0.01% 3963
2024
Q4 		$97 Buy
+12
New +$110 ﹤0.01% 4045

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

IFP Advisors's ORIC Position: Q1 2026 in Review

IFP Advisors held its Oric Pharmaceuticals (ORIC) position steady in Q1 2026 at 297 shares worth $3.76K. The position accounts for ﹤0.01% of the portfolio, ranked #3691.

IFP Advisors first reported a position in ORIC in Q4 2024 and has held it in 6 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • IFP Advisors held 297 shares of Oric Pharmaceuticals worth $3.76K as of Q1 2026.
  • IFP Advisors left its Oric Pharmaceuticals share count unchanged in Q1 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #3691 holding.
  • IFP Advisors first reported a position in Oric Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.